Genetics improve risk assessment in AMD
October 23rd 2013Inclusion of clinically relevant genetic markers improves the accuracy of predicting risk of progression to choroidal neovascularization (CNV) in patients with age-related macular degeneration (AMD) beyond a prediction based on only phenotypic risk factors, according to a recent cohort study.
G-BA finds Jetrea benefits VMT patients
October 23rd 2013The final early benefit assessment from the German Federal Joint Committee (G-BA) has concluded that ThromboGenics’ ocriplasmin (Jetrea) demonstrates significant added benefit for vitreomacular traction (VMT) patients with mild and moderate symptoms.